Sagimet Biosciences (STU:0O2) Change In Inventory : €0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Sagimet Biosciences Change In Inventory?

Sagimet Biosciences's change in inventory for the quarter that ended in Dec. 2024 was €0.00 Mil. It means Sagimet Biosciences's inventory stayed the same from Sep. 2024 to Dec. 2024 .

Sagimet Biosciences's change in inventory for the fiscal year that ended in Dec. 2024 was €0.00 Mil. It means Sagimet Biosciences's inventory stayed the same from Dec. 2023 to Dec. 2024 .

Sagimet Biosciences's Total Inventories for the quarter that ended in Dec. 2024 was €0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Sagimet Biosciences Change In Inventory Historical Data

The historical data trend for Sagimet Biosciences's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sagimet Biosciences Change In Inventory Chart

Sagimet Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Inventory

Get a 7-Day Free Trial

Sagimet Biosciences Quarterly Data
	Dec19	Mar20	Dec20	Mar21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Inventory	Get a 7-Day Free Trial												-	-	-	-	-

Sagimet Biosciences Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Sagimet Biosciences (STU:0O2) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Sagimet Biosciences's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Sagimet Biosciences's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Sagimet Biosciences's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Sagimet Biosciences Change In Inventory Related Terms

Thank you for viewing the detailed overview of Sagimet Biosciences's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Sagimet Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sagimet Biosciences Inc (STU:0O2) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

SGMT:USA 0O2:Germany

Address

155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402

Website

https://www.sagimet.com

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Sagimet Biosciences Headlines

No Headlines